Determination of Myxovirus Resistance Protein A as a New Biomarker of Viral Infection

The development of new methods in the field of detection of viral and bacterial pathogens represents a major challenge. A group of acute-phase proteins has been described, including C-reactive protein (CRP), interleukin-6 (IL-6), calprotectin, procalcitonin, serum amyloid A, and MxA (Myxovirus resistance protein A). Their concentration ranges are also highly diverse. Their clinical relevance ranges from distinguishing the nature of the infectious agent (bacteria, virus) to trauma and predictive significance in neoplastic diseases. In routine clinical laboratory medicine, the detection of C-reactive protein levels is standardly used. Recently, however, the MxA molecule has emerged as a new biomarker of viral diseases. This protein has been tested in clinical laboratory practice since 2024, and more than 8,000 determinations have been carried out to date. The bioanalytical determination of the protein is performed using the lateral flow chromatography method, and the detection of the colored product is spectral. Based on available data on the reproducibility of the measuring system, the MxA reference value was calculated for concentration I: 20.3 ± 2.1 ng mL–1, for concentration II 128 ± 13 ng mL–1, and the average bias (%) hovered around –15 %. Experimentally, the MxA level was monitored during vaccination against dengue fever. Initially, the MxA level was around 10 ng mL–1. Within 24 hours, it rose to 59 ng mL–1, after 48 hours it was 22 ng mL–1, and after 196 hours it returned to the baseline of 10 ng mL–1. Furthermore, it was possible to identify the primary diagnosis from the hospital information system, and thus segment the obtained data. Both the median and average MxA concentrations are higher in diseases caused by viruses (above 200 ng mL–1). This was also demonstrated by ROC analysis with an area under the curve (AUC) of 0.58. It was found that the determination of MxA protein in combination with CRP represents a highly valuable examination for the early diagnosis of viral infection and for its differentiation from bacterial infection. High values of both proteins may then indicate a combined infection.

Authors

Institutions

Publication Details

Journal
Chemické listy
Published
2026-11-15
DOI
https://doi.org/10.54779/chl20260695
Primary Topic
Biomarkers in Disease Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Determination of Myxovirus Resistance Protein A as a New Biomarker of Viral Infection

Jan Illner, René Kizek, Petra Bukovska, Eva Klapková et al.
Chemické listy
Biomarkers in Disease Mechanisms
article

Determination of Myxovirus Resistance Protein A as a New Biomarker of Viral Infection

Jan Illner, René Kizek, Petra Bukovska, Eva Klapková, Richard Průša, Karel Kotaška, Julia Werle, Ondřej Mitrovský, Katerina Stefanova, Petr Lehnert
article en

Abstract

The development of new methods in the field of detection of viral and bacterial pathogens represents a major challenge. A group of acute-phase proteins has been described, including C-reactive protein (CRP), interleukin-6 (IL-6), calprotectin, procalcitonin, serum amyloid A, and MxA (Myxovirus resistance protein A). Their concentration ranges are also highly diverse. Their clinical relevance ranges from distinguishing the nature of the infectious agent (bacteria, virus) to trauma and predictive significance in neoplastic diseases. In routine clinical laboratory medicine, the detection of C-reactive protein levels is standardly used. Recently, however, the MxA molecule has emerged as a new biomarker of viral diseases. This protein has been tested in clinical laboratory practice since 2024, and more than 8,000 determinations have been carried out to date. The bioanalytical determination of the protein is performed using the lateral flow chromatography method, and the detection of the colored product is spectral. Based on available data on the reproducibility of the measuring system, the MxA reference value was calculated for concentration I: 20.3 ± 2.1 ng mL–1, for concentration II 128 ± 13 ng mL–1, and the average bias (%) hovered around –15 %. Experimentally, the MxA level was monitored during vaccination against dengue fever. Initially, the MxA level was around 10 ng mL–1. Within 24 hours, it rose to 59 ng mL–1, after 48 hours it was 22 ng mL–1, and after 196 hours it returned to the baseline of 10 ng mL–1. Furthermore, it was possible to identify the primary diagnosis from the hospital information system, and thus segment the obtained data. Both the median and average MxA concentrations are higher in diseases caused by viruses (above 200 ng mL–1). This was also demonstrated by ROC analysis with an area under the curve (AUC) of 0.58. It was found that the determination of MxA protein in combination with CRP represents a highly valuable examination for the early diagnosis of viral infection and for its differentiation from bacterial infection. High values of both proteins may then indicate a combined infection.

Chemické listyVol. 120(11)
University Hospital in Motol (CZ), Fakultní nemocnice Motol a Homolka (CZ)
Biomarkers in Disease Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon